[4] HORN L, BAUML J, FORDE P M, et al. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer[J]. Lung Cancer, 2019, 128: 74-90. [5] MARCHETTI A, FELICIONI L, MALATESTA S, et al. Clinical features and outcome of pati...
[3] LEONETTI A, FACCHINETTI F, ROSSI G, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall[J]. Cancer Treat Rev, 2018, 66: 82-94. [4] HORN L, BAUML J, FORDE P M, et al. Real-world treatment patterns and survival of patients with BRAF ...
IntroductionBRAF is a proto-oncogene encoding a serine/ threonine protein kinase which is a downstream effector of RAS and transduces signals through the MAPK pathway to promote cell proliferation and survival. Although BRAF mutations are commonly seen in melanoma and papillary thyroid cancer, other ...
Efficacy of Vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: An open label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol, 2019, 3: PO.18.00266. [8]Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in ...
[7]Subbiah V, Gervais R, Riely G, et al. Efficacy of Vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: An open label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol, ...
随着对肿瘤分子水平研究的不断深入,BRAF突变已被确定为各种恶性肿瘤生长的驱动因素,其中BRAF V600突变在肺癌中占2%-4%。临床对于携BRAF突变非小细胞肺癌(NSCLC)的治疗,使用传统的化疗或新型的免疫治疗,疗效获益有限,而达拉非尼+曲美替尼(简称“D+T”...
At present, there are many clinical trials on BRAF⁃mutation NSCLC and new drugs constantly emerging. However, there is no standardized consensus on the diagnosis and treatment of BRAF⁃mutation NSCLC in China. The expert group of the Lung Cancer Professional Committee of the Chinese Anti⁃...
非小细胞肺癌(non-small cell lung cancer, NSCLC)是临床最常见的肺癌类型,占所有肺癌的85%。BRAF是丝裂原活化蛋白激酶(mitogen-activated protein kinase, MAPK)/细胞外信号调节激酶(extracellular signal-regulated kinases, ERK)信号通路的关键分子。BRAF突变最初在黑色素瘤中发现,随后在结直肠癌、甲状腺乳头状癌和...
ATC is an aggressive cancer which has a poor prognosis and survival rate of only 3 to 5 months with treatment. Novel therapies for this patient population are needed, especially for those with a BRAF mutation. The phase 2 ANAPLAST-NEO study (NCT04739566) was created to test the effic...
[4] Kuiper J. L., Hendriks L. E., van der Wekken A. J., et al. Treatment and survival of patients withEGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis [J]. ...